Enveric Biosciences (Enveric Biosciences) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Enveric Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Enveric Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Enveric Biosciences Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Enveric Biosciences's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Short-Term Debt & Capital Lease Obligation Chart

Enveric Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

4.88

0.11

0.06

Enveric Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.04	0.01	-	-	-

Enveric Biosciences Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Enveric Biosciences Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences (Enveric Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SLZA:Germany

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Executives

Frank Pasqualone	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney	officer: Chief Financial Officer	10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey	officer: Chief Financial Officer	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil	director	C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson	director	1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel	officer: Chief Technical Officer	3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker	director, officer: Chief Executive Officer	3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini	officer: Chief Scientific Officer	155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward	officer: Chief Financial Officer	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind	director
Marcus Schabacker	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer	director	150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson	director, officer: CEO and Chairman	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins	officer: Chief Medical Officer	C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103